The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans Bonnie Ky, MD,* Anne Burke, MD,* Sotirios Tsimikas, MD, Mahlet G. Tadesse, SCD,* Philippe O. Szapary, MD, etc Philadelphia, Pennsylvania Vol. 51, No. 17, 2008, JACC
Background HMG-Co A reductase inhibitors reduce LDL-C & Cardiovascular risk
Effects on circulating biomarkers of reactive oxidative stress are not well-defined Smaller studies : Statin therapy might reduce the urinary excretion or plasma levels of the isoprostane 8 - iso - IPF2-III
Impact of statins on oxidative stress Many of the aforementioned studies : not well controlled and require confirmation with rigorous methodology The question of statin dose-response on oxidative stress has not been addressed. Equivalent doses of statins have never been compared with each other in a human study with regard to effects on oxidative stress
Objectives Determine the effects of pravastatin and atorvastatin on markers of oxidative stress in plasma.
Methods Subjects 120 healthy subjects ( 21 and 80 years ) LDL-C ; 130 ~ 220 mg/dl ( no lipid-lowering therapy ) Exclusion criteria Exposure to cholesterol-modulating drugs ( 6wks ) Known CHD, diabetes or fasting glucose 126 mg/dl Significant renal or hepatic disease Triglycerides 500 mg/dl Familial hypercholesterolemia Pregnant or lactating women
Study design Randomization in a 1:1:1:1 Pravastatin 40 mg/day ( Prava40 ) Atorvastatin 10 mg/day ( Atorva10 ) Atorvastatin 80 mg/day ( Atorva80 ) Placebo After 8wks & 16 wks Fasting blood work 12-h urine collection Adverse event reporting & study medication Laboratory analyses
Laboratory measurements Lipid parameters Plasma total cholesterol ( TC ) High-density lipoprotein cholesterol ( HDL-C ) TG levels LDL-C VLDL levels Apolipoprotein B ( apoB ) Concentrations of oxidized LDL ( OxLDL ) Phospholipase A2 ( Lp-PLA2 ) Content of OxPL/apoB OxPL/apoB & IC/apoB 8, 12-iso-iPF2-VI the most abundant isoprostane detected in human urine
Results Baseline characteristics and study completion Lipid parameters Urinary 8, 12-iso-iPF2-VI Oxidized LDL Lp-PLA2 OxPL/apoB assay Autoantibodies to MDA-LDL and apoB immune complexes Correlation between markers of oxidative stress at baseline Correlation between changes in markers of oxidative stress after statin therapy
Baseline characteristics & study completion
Lipid parameters No significant differences in baseline lipid values among the groups. All statin-treated groups experienced significant reductions in TC, LDL-C, apoB, and non–HDL-C
Urinary 8, 12-iso-iPF2-VI No significant difference in the log transformed excretion of the F2 isoprostane across the 4 treatment groups
Oxidized LDL (Mercodia assay) No significant differences in baseline OxLDL After 16 weeks: all statin-treated groups experienced a reduction in OxLDL
Lp-PLA2 Both pravastatin and atorvastatin led to significant decreases in Lp-PLA2 mass Lp-PLA2 mass correlated strongly with LDL-C and apoB levels atorva10 & prava40 remained significant
OxPL/apoB assay No statistically significant differences in OxPL/apoB at baseline After 16 weeks : significant increases were noted across the 3 groups with prava40, atorva80 increase in OxPL/apoB Lp(a) increased significantly in parallel with OxPL/apoB:
Autoantibodies to MDA-LDL and apoB immune complexes No statistically significant differences in MDA-LDL autoantibodies or IC formation at baseline. After 16 weeks : statin therapy there were no significant changes in IgG or IgM autoantibodies to MDA-LDL or IgG or IgM IC/apoB All 3 statin-treated arms led to a trend in reduction in total apoB-IC content
Correlation between markers of oxidative stress at baseline Mercodia OxLDL correlated strongly with apoB & LDL at baseline
Correlation between changes in markers of oxidative stress after statin therapy Changes in Mercodia OxLDL strongly correlated with changes in apoB, LDL-C, Lp-PLA2
Discussion Statins reduced LDL-C and non–HDL-C as expected but had variable effects on levels of several distinct biomarkers of oxidative stress Isoprostanes : sensitive and reliable measures of lipid peroxidation in vivo
Possible explanations for the lack of change in isoprostane excretion in our study The most likely is that statin therapy did not suppress lipid peroxidation in this population Only when endogenous antioxidant defenses are depleted In spite of the study randomization, the distribution of smokers > greater proportion in the placebo arm The Mercodia OxLDL assay
Bruneck study : OxPL/apoB were significantly associated with cardiovascular events Statistically significant increase in OxPL/apoB has been observed in response to diet or treatment with atorvastatin or pravastatin > paradoxical During early atherosclerosis regression, the increase in OxPL/apoB levels in plasma might reflect a beneficial effect of diet and perhaps statins on the vessel wall
Lp-PL A2 : proatherogenic and proinflammatory Levels of Lp-PLA2 : strong association with cardiovascular risk Lp- PLA2 activity potentiated the increased risk of death and cardiac events : associated with elevated OxPL/apoB or Lp(a)
Study limitations Prospective study and the first to measure all these oxidative biomarkers in the same subset Modest size These findings will need to be validated in larger studies
Conclusions Statin therapy results in variable effects on oxidative stress markers in hypercholesterolemic subjects. Future outcome studies should collectively assess various oxidative markers to define clinical utility